[Long-term antithrombotic strategies in post-myocardial infarction patients]

Area of Science:

• Cardiology
• Vascular Medicine
• Pharmacology

Background:

• Acute coronary events (ACE) necessitate strategies to mitigate future ischemic risks.
• Residual risk in patients with prior ACE contributes to significant morbidity and healthcare expenditure.
• Secondary prevention aims to reduce recurrent events and improve long-term patient prognosis.

Purpose of the Study:

• To review current antithrombotic strategies for patients with a history of acute coronary events.
• To emphasize the importance of identifying and managing residual ischemic risk.
• To guide therapeutic choices for optimal long-term outcomes in this patient population.

Main Methods:

• Review of existing literature on antithrombotic therapies and secondary prevention post-acute coronary events.
• Analysis of the role of dual antiplatelet therapy (DAPT) in managing patients with previous ACE.
• Discussion on risk stratification for ischemic events and bleeding complications.

Main Results:

• Dual antiplatelet therapy (DAPT) demonstrates high efficacy in reducing thrombotic complications within 12 months and long-term post-ACE.
• Effective secondary prevention measures, including antithrombotic treatment, are available.
• Balancing antithrombotic efficacy with bleeding risk is critical for optimizing treatment.

Conclusions:

• Personalized therapeutic strategies are essential for patients with prior ACE, considering both residual ischemic risk and bleeding potential.
• Optimizing antithrombotic therapy is fundamental for improving long-term prognosis and reducing healthcare costs.
• Continued focus on long-term residual ischemic risk reduction is paramount in managing patients post-acute coronary events.